SALV.L

SalvaRx Group Plc
SalvaRx Group plc - Change of Nominated Adviser and Broker
31st January 2019, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5979O
SalvaRx Group plc
31 January 2019
 

SalvaRx Group plc

("SalvaRx" or the "Company")

Change of Nominated Adviser and Broker

SalvaRx (AIM: SALV), the drug discovery and development company focused on cancer immunotherapy, announces that pursuant to the proposed merger between SP Angel Corporate Finance LLP ("SP Angel") and Northland Capital Partners Ltd, it has appointed SP Angel as its Nominated Adviser and Joint Broker with immediate effect. 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

 SalvaRx Group plc


Denham Eke, Chief Financial Officer

Tel: +44 (0) 01624 639396

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Tel: +44 (0) 20 3470 0470

 

Matthew Johnson / Lindsay Mair (Corporate Finance)


Peterhouse Capital Limited

Joint Broker

Lucy Williams / Duncan Vasey

Tel: +44 (0) 20 7469 0932

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
APPFMGFMNGLGLZM ]]>
TwitterFacebookLinkedIn